OpGen, Inc. (NASDAQ:OPGN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Tuesday. The firm currently has a $0.25 price objective on the medical research company’s stock. Zacks Investment Research‘s price objective would indicate a potential downside of 10.71% from the stock’s previous close.
According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “
Separately, HC Wainwright reiterated a “buy” rating and set a $1.00 price objective on shares of OpGen in a research note on Tuesday, October 24th.
Shares of OpGen (OPGN) opened at $0.28 on Tuesday. OpGen has a 12 month low of $0.21 and a 12 month high of $3.10. The company has a quick ratio of 0.19, a current ratio of 0.29 and a debt-to-equity ratio of -0.55.
WARNING: This piece was first reported by Transcript Daily and is owned by of Transcript Daily. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://transcriptdaily.com/2017/11/14/zacks-investment-research-upgrades-opgen-inc-opgn-to-buy.html.
An institutional investor recently bought a new position in OpGen stock. Perkins Capital Management Inc. purchased a new stake in OpGen, Inc. (NASDAQ:OPGN) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,400,000 shares of the medical research company’s stock, valued at approximately $434,000. Perkins Capital Management Inc. owned 2.72% of OpGen at the end of the most recent quarter. Institutional investors and hedge funds own 10.90% of the company’s stock.
OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.
Receive News & Ratings for OpGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.